“Even with correlation of metastasis to the CCR5
Post# of 148253
(Total Views: 390)
Posted On: 08/17/2019 10:42:31 AM
“Even with correlation of metastasis to the CCR5 receptor, the cancers AT BEST CASE SCENARIO, will allow for a longer period of remission, before the cancer reemerges.”
Leronlimab has an amazing safety profile, with few, if any, side effects. Now consider the side effects of most oncology drugs and the remission periods or extension of life that those drugs offer. If leronlimab can do the same, or just slightly better, it will be a huge hit because of the lack of leronlimab’s side effects. So you’re best case scenario would still be a game changer for those with cancers that are treatable by leronlimab.
Leronlimab has an amazing safety profile, with few, if any, side effects. Now consider the side effects of most oncology drugs and the remission periods or extension of life that those drugs offer. If leronlimab can do the same, or just slightly better, it will be a huge hit because of the lack of leronlimab’s side effects. So you’re best case scenario would still be a game changer for those with cancers that are treatable by leronlimab.
(0)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼